AIRLINK 72.68 Decreased By ▼ -1.42 (-1.92%)
BOP 5.06 Increased By ▲ 0.06 (1.2%)
CNERGY 4.35 Increased By ▲ 0.01 (0.23%)
DFML 29.87 Increased By ▲ 0.33 (1.12%)
DGKC 84.50 Increased By ▲ 0.95 (1.14%)
FCCL 22.32 Decreased By ▼ -0.11 (-0.49%)
FFBL 34.30 Decreased By ▼ -0.60 (-1.72%)
FFL 10.20 Increased By ▲ 0.33 (3.34%)
GGL 10.33 Increased By ▲ 0.33 (3.3%)
HBL 112.80 Increased By ▲ 0.80 (0.71%)
HUBC 140.51 Increased By ▲ 2.82 (2.05%)
HUMNL 8.03 Increased By ▲ 1.05 (15.04%)
KEL 4.51 Increased By ▲ 0.11 (2.5%)
KOSM 4.60 Increased By ▲ 0.01 (0.22%)
MLCF 38.65 Increased By ▲ 0.10 (0.26%)
OGDC 135.00 Decreased By ▼ -1.60 (-1.17%)
PAEL 26.55 Increased By ▲ 1.41 (5.61%)
PIAA 26.14 Decreased By ▼ -0.37 (-1.4%)
PIBTL 6.60 Decreased By ▼ -0.05 (-0.75%)
PPL 122.92 Decreased By ▼ -2.48 (-1.98%)
PRL 28.31 Increased By ▲ 0.10 (0.35%)
PTC 13.93 Decreased By ▼ -0.37 (-2.59%)
SEARL 54.93 Increased By ▲ 0.33 (0.6%)
SNGP 70.50 Decreased By ▼ -0.70 (-0.98%)
SSGC 10.45 Decreased By ▼ -0.05 (-0.48%)
TELE 8.58 Increased By ▲ 0.06 (0.7%)
TPLP 11.00 Increased By ▲ 0.06 (0.55%)
TRG 61.55 Increased By ▲ 0.85 (1.4%)
UNITY 25.25 Decreased By ▼ -0.08 (-0.32%)
WTL 1.31 Increased By ▲ 0.05 (3.97%)
BR100 7,666 Increased By 1.3 (0.02%)
BR30 25,129 Increased By 103.3 (0.41%)
KSE100 73,134 Increased By 369.5 (0.51%)
KSE30 23,748 Decreased By -27.7 (-0.12%)

Asad Umar launches phase 3 trials of coronavirus vaccine

  • Result is expected in 4 to 6 months, Umar said.
Published September 22, 2020

Minister of Planning and Development Asad Umar announced on Tuesday that the phase three trials for a coronavirus vaccine in Pakistan has been launched.

In a tweet today, the minister said that phase three trials for the vaccine developed by a Chinese company, China’s CanSino Biologics has been launched. He further said a total of 40,000 people will participate in this trial in 7 countries.

Out of these 40,000 people, 8000 to 10000 will be Pakistanis, Umar said. "Initial results expected in 4 to 6 months," the minister added.

Addressing a presser today, the National Institute of Health Executive Director Major General Aamer Ikram said that the CanSino vaccine is based on recombinant technology. He said the vaccine will be administered to the volunteers after a medical examination.

He said although the NIH would follow up with them for 12 months, the results of the vaccine would be expected in three months.

Comments

Comments are closed.